media1

Group News

Aspen’s half-year revenue increases 13% to R19.8 billion

March 9, 2017

Johannesburg – JSE Limited listed Aspen Pharmacare Holdings Limited (APN), a leading pharmaceutical company in the southern hemisphere, has announced favourable results for the six months ended 31 December 2016. Stephen Saad, Aspen Group Chief Executive said, “The Group has transformed into a global multinational organisation focused on therapeutic specialties over the past few years.…

Read More >>

Stephen Saad receives the coveted CNBC Africa Entrepreneur of the Year Award

November 30, 2016

Stephen Saad’s acceptance speech for the Entrepreneur of the Year Award at AABLA.

Read More >>

Stephen Saad scoops Entrepreneur of the Year Award

September 30, 2016

Johannesburg. Stephen Saad, Aspen Group Chief Executive, was announced as the winner of the Entrepreneur of the Year Award at the All Africa Business Leaders Awards (AABLA) gala banquet in Johannesburg. At the Awards, hosted in partnership with CNBC Africa, Stephen Saad said, “You work at something and you build something together with the team…

Read More >>

Aspen’s comparable revenue increases by 12% to R35.4 billion

September 14, 2016

Aspen’s comparable revenue increases by 12% to R35.4 billion Johannesburg – JSE Limited listed Aspen Pharmacare Holdings Limited (APN), a leading pharmaceutical company in the southern hemisphere, has announced positive results for the year ended 30 June 2016 notwithstanding economic pressures and currency weaknesses.   Stephen Saad, Aspen Group Chief Executive said, “The positive results…

Read More >>

Aspen AstraZeneca Anaesthetics Portfolio Agreement

June 9, 2016

Aspen Holdings is pleased to announce that its wholly owned subsidiary, Aspen Global Incorporated (“AGI”), has signed an agreement with AstraZeneca AB and AstraZeneca UK (“AstraZeneca”) whereby AGI will acquire the exclusive rights to commercialise AstraZeneca’s global (excluding the USA) anaesthetics portfolio (“the Transaction”). AstraZeneca’s anaesthetics portfolio comprises seven established medicines, namely Diprivan (general anaesthesia),…

Read More >>

Aspen demonstrates economic growth and specialized technologies contributions to Deputy President Cyril Ramaphosa

April 14, 2016

Port Elizabeth. JSE-listed Aspen, the largest pharmaceutical manufacturer in the southern hemisphere, earlier today hosted Deputy President Cyril Ramaphosa and Minister of Health Dr Aaron Motsoaledi at its Port Elizabeth-based flagship manufacturing site. The visit provided an opportunity to discuss Aspen’s economic growth and export contributions to South Africa, and to demonstrate its globally recognised…

Read More >>

Aspen’s profit after tax increases by 35%

March 3, 2016

Aspen’s profit after tax increases by 35% Johannesburg – JSE Limited listed Aspen Pharmacare Holdings Limited (APN), a leading pharmaceutical manufacturer in the southern hemisphere, has announced pleasing results for the six months ended 31 December 2015. The Group delivered solid growth in a period marked by economic stress and weakening market currencies. The factors…

Read More >>

Aspen’s revenue increases 22% to R36 billion

September 9, 2015

Johannesburg – JSE Limited listed Aspen Pharmacare Holdings Limited (APN), the sixth largest generic company in the world, has announced excellent results for the year ended 30 June 2015. These results benefitted from the contribution of acquisitions concluded during the prior year. GROUP PERFORMANCE Revenue increased by 22% to R36.1 billion. Operating profit rose by…

Read More >>

Divestment of portfolio of branded and generic products to Strides entities

May 21, 2015

Aspen is pleased to announce that certain of its wholly owned Australian subsidiaries (collectively “Aspen Australia”), have entered into an agreement with Strides (Australia) Pharma Pty Ltd (“Strides Australia”), a company incorporated in Australia, in terms whereof Aspen Australia will divest to Strides Australia, a portfolio of approximately 130 products for a consideration of approximately…

Read More >>

Cautionary Announcement

May 14, 2015

Shareholders are advised that Aspen is currently engaged in discussions regarding a possible acquisition of an infant nutritionals business. These discussions may have a material effect on the price of Aspen’s securities if successfully concluded and accordingly shareholders are advised to exercise caution when dealing in the Company’s securities. Durban 14 May 2015 Sponsor                                                                         Investec…

Read More >>